Radiation Therapy News and Research

RSS

Radiation therapy (also called radiotherapy, x-ray therapy, or irradiation) is the use of a certain type of energy (called ionizing radiation) to kill cancer cells and shrink tumors. Radiation therapy injures or destroys cells in the area being treated (the “target tissue”) by damaging their genetic material, making it impossible for these cells to continue to grow and divide. Although radiation damages both cancer cells and normal cells, most normal cells can recover from the effects of radiation and function properly. The goal of radiation therapy is to damage as many cancer cells as possible, while limiting harm to nearby healthy tissue.

Lawson researchers find radiation-resistant stem cell population in the colon linked to cancer growth

Researchers at Lawson Health Research Institute have identified a new stem cell population in the colon linked to cancer growth. The findings, which were recently published in the prominent journal Cell Stem Cell, will significantly change the way we study and treat colon cancer.

16 Jun 2015

Stage IIIB NSCLC patients may benefit from surgical resection in combination with chemo or radiation therapy

Patients diagnosed with an advanced form of metastatic non-small cell lung cancer (NSCLC) may benefit from surgical resection (removal of all or part of the lung) in combination with chemotherapy and radiation therapy, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.

11 Jun 2015

Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Elekta has signed a contract with one of Korea's most advanced hospitals, Samsung Medical Center in Seoul, to deliver the first Leksell Gamma Knife Icon to Asia.

From Elekta 10 Jun 2015

Surgical resection, chemo and radiation therapy combination may help treat metastatic lung cancer

10 Jun 2015

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

Elekta's Leksell Gamma Knife Icon precision radiosurgery system CE marked

Elekta has CE marked its Leksell Gamma Knife Icon precision radiosurgery system, making this latest generation Leksell Gamma Knife platform available in the European market.

From Elekta 10 Jun 2015

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Researchers at VCU Massey Cancer Center's Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival.

10 Jun 2015

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

Actavis plc, which recently completed the acquisition of Allergan, Inc., today announced that the company has received approval from the U.S. Food and Drug Administration to market NATRELLE INSPIRA round gel-filled textured breast implants, offering women undergoing reconstruction, augmentation or revision surgery another breast shaping option for a customized result.

5 Jun 2015

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

To date, there is no drug approved for medical therapy of chordoma patients. Supporting research for chordoma (a very rare cancer arising from the skull base or the spine and affecting only one person in a million per year) was the focus of talks that took place on 30 April 2015 at the European Medicines Agency in London. The workshop was attended by patients, oncologists, pathologists, regulators, statisticians and industry representatives.

4 Jun 2015

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

New findings suggest that a gene called IDH1 might be prognostic marker for a rare form of brain cancer. Patients in this study who had a mutated IDH gene lived an average of 7.9 years after diagnosis versus 2.8 years for patients with unaltered IDH.

4 Jun 2015

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Varian Medical Systems today announced that it has been selected to equip and service the new multi-room HollandPTC in Delft with the Varian ProBeam proton therapy system. The company will book the equipment part of the order in its fiscal 2015 third quarter.

3 Jun 2015

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

OncoGenex Pharmaceuticals, Inc. announced that results from an exploratory analysis of the Phase 2 Borealis-1 trial showed that metastatic bladder cancer patients with poor prognostic features benefited from apatorsen 600mg added to first-line chemotherapy compared to chemotherapy alone.

2 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

New treatment option for postmenopausal women with non-invasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen.

2 Jun 2015

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

GenomeDx Biosciences today announced that the robust Decipher genomic analysis platform, successfully classified various subtypes of bladder cancer based on the genomic expression of certain biomarkers, including one type associated with resistance to cisplatin-based chemotherapy. Importantly, this unique genomic signature has potential as a tool to predict tumor responsiveness to neoadjuvant chemotherapy in patients with muscle-invasive bladder cancers (MIBC).

2 Jun 2015

Surgical resection, chemo and radiation therapy combination could benefit metastatic NSCLC patients

2 Jun 2015

SIRFLOX study promises better and earlier treatment option for liver cancer patients

The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic colorectal cancer (mCRC) reported in the SIRFLOX study, were presented at the American Society of Clinical Oncology Annual Meeting in Chicago.

2 Jun 2015

WBRT associated with worse cognitive function than radiosurgery, shows study

Whole Brain Radiation Therapy (WBRT) is associated with significantly worse cognitive function than radiosurgery, and should no longer be used in the adjuvant setting after radiosurgery to treat cancer patients with brain metastases, according to a large study led by a researcher at The University of Texas MD Anderson Cancer Center.

1 Jun 2015

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015.

1 Jun 2015

Radiation Therapy News and Research

Further Reading

Lawson researchers find radiation-resistant stem cell population in the colon linked to cancer growth

Stage IIIB NSCLC patients may benefit from surgical resection in combination with chemo or radiation therapy

Elekta inks contract with Samsung Medical Center to provide the first Leksell Gamma Knife Icon to Asia

Surgical resection, chemo and radiation therapy combination may help treat metastatic lung cancer

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

Elekta's Leksell Gamma Knife Icon precision radiosurgery system CE marked

Massey researchers aim to develop models that can predict complications from stem cell transplantation

Actavis receives FDA approval to market NATRELLE INSPIRA round gel-filled textured breast implants

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

New study suggests that IDH1 gene may be prognostic marker for anaplastic astrocytoma

Varian selected to equip, service HollandPTC in Delft with ProBeam proton therapy system

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

New treatment option for postmenopausal women with non-invasive breast cancer

Decipher genomic analysis platform predicts tumor responsiveness to neoadjuvant chemotherapy in MIBC patients

Surgical resection, chemo and radiation therapy combination could benefit metastatic NSCLC patients

SIRFLOX study promises better and earlier treatment option for liver cancer patients

WBRT associated with worse cognitive function than radiosurgery, shows study

Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News